CytomX shareholders elect McCarthy and Mohindru as directors, ratify E&Y, approve exec comp

CytomX Therapeutics, Inc.

Class I directors Sean McCarthy and Mani Mohindru elected with ~68% of votes cast.
Ratification of Ernst & Young as auditor for FY2022 passed with 99.95% of votes cast.
Non-binding advisory vote on named executive officer compensation approved with ~93% support.
All proposals passed; broker non-votes recorded for directors and say-on-pay only.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.